Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Regal Investment Advisors LLC

Regal Investment Advisors LLC grew its position in Amgen Inc. (NASDAQ:AMGN) by 1.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 4,171 shares of the medical research company’s stock after acquiring an additional 63 shares during the quarter. Regal Investment Advisors LLC’s holdings in Amgen were worth $1,303,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Grassi Investment Management acquired a new stake in shares of Amgen during the first quarter worth $2,283,000. Public Employees Retirement System of Ohio lifted its holdings in shares of Amgen by 1.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 281,791 shares of the medical research company’s stock worth $81,161,000 after purchasing an additional 4,376 shares during the period. Meyer Handelman Co. lifted its holdings in shares of Amgen by 7.2% during the second quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after purchasing an additional 8,700 shares during the period. Chicago Partners Investment Group LLC lifted its holdings in shares of Amgen by 1.3% during the fourth quarter. Chicago Partners Investment Group LLC now owns 4,543 shares of the medical research company’s stock worth $1,388,000 after purchasing an additional 57 shares during the period. Finally, Novak & Powell Financial Services Inc. acquired a new stake in shares of Amgen during the fourth quarter worth $803,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Argus increased their price objective on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Bank of America increased their price objective on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald assumed coverage on Amgen in a research report on Friday. They issued an “overweight” rating and a $405.00 price objective for the company. Finally, Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $320.00 to $335.00 in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and a consensus target price of $325.55.

Amgen Stock Down 0.1 %

Shares of NASDAQ:AMGN opened at $322.21 on Tuesday. The stock’s 50-day moving average price is $328.49 and its two-hundred day moving average price is $308.12. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85. The firm has a market cap of $172.84 billion, a price-to-earnings ratio of 46.03, a PEG ratio of 2.98 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same period in the previous year, the business posted $5.00 earnings per share. The firm’s quarterly revenue was up 20.1% on a year-over-year basis. On average, research analysts forecast that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.79%. The ex-dividend date was Friday, August 16th. Amgen’s payout ratio is 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.